Home MarketAarti Drugs Ltd.

Aarti Drugs Ltd. Stock Info: As on 2017-11-24 15:55:32

Nse

535.05

-0.10(-0.02%)
Change%
52 Week Range
447.80
24.00
665.00
9.00
Open532.55
Day's Range428.12 - 642.18
Value Traded (in ₹ Cr.) 0.16

Bse

532.10

0.10(0.02%)
Change %
52 Week Range
456.25
24.00
665.00
9.00
Open536.00
Day's Range425.60 - 638.40
Value Traded (in ₹ Cr.) 0.01

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 14,907,806.00 62.49%
Mutual Funds/UTI 877,023.00 3.68%
FII 163,419.00 0.68%
Employee 0.00 0.00%
Public 6,798,546.00 28.50%
Government 0.00 0.00%
Others 917,743.00 3.85%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 1.02
Basic EPS (Rs.) 27.37
Cash EPS 42.06
BVPerShare Excl 144.66
Operating Revenue 444.11
PBDITPerShare 70.90
Dividend 6.75
NPPerShare 27.37
Current Ratio 1.14
Quick Ratio 0.78
PriceToBV 3.14
Earnings 0.06
PBDIT Margin 15.96
PBT Margin 8.63
NP Margin 6.16
Return On Assets 6.28
Retention Ratios 75.33
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 1,075.50
Total Expenses 982.66
EBITDA 171.70
PBT 92.84
PAT 66.29
Net Income 66.29
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 554.18
Total Expenses 486.08
EBITDA 50.03
PBT 45.77
PAT 33.72
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 24.22
Net worth 350.31
Investments 11.12
Total Liability 1,054.70
Total debt 432.58
Net block 496.81
Total Assets 1,054.70
Parameter Mar-16 (₹ Cr.) 6M % change
Total share capital 24.22
Net worth 350.31
Investments 11.12
Total Liability 1,054.70
Total debt 432.58
Net block 496.81
Total Assets 1,054.70
Company Curr Price Prev. Close Change% W's Low/High

Abbott India Ltd.

4977.5 4858.7 2.45
4810.055049

Ajanta Pharma Ltd.

1329.2 1327.15 0.15
1281.151362.3

Albert David Ltd.

361.2 323.55 11.64
286.1374

Alembic Ltd.

39.35 39.25 0.25
3940.2

Alembic Pharmaceuticals Ltd.

515.5 514.3 0.23
507.4520.4

Alkem Laboratories Ltd.

1987.9 1974.45 0.68
19442013.85

Alpa Laboratories Ltd.

32.35 32.3 0.15
3133.5
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

56.5 53.35 5.9
44.0558.4

Aayush Food & Herbs Ltd.

47.7 47.9 -0.42
45.0552.7

Abbott India Ltd.

4968.65 4861.15 2.21
4825.655085

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3

Advik Laboratories Ltd.

5.7 5.99 -4.84
5.76.27
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 125.27
Cash from investing activities -87.40
Cash from financing activities -36.79
Net change in cash 1.07

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
DSP BlackRock Micro-Cap Fund 0.76%

Excel Industries Q2 net profit jumps 60.26% at Rs 11.01 cr

The company reported standalone net profit of Rs 11.01 crore for the quarter ended September 30, 2017 as compared to Rs 6.87 crore in the same period last year, registering a year-on-year growth of 60.26 per cent. Net revenue of the company rose moderately by 6.02 per cent at Rs 130.02 crore in July-September quarter of this fiscal as against Rs 122.64 crore in the corresponding period last year. During July-September quarter, operating expenses dropped by 0.72 per cent to Rs 108.27 crore from Rs 109.05 crore in year ago period. Other Income dipped by 71.76 per cent at Rs 0.24 crore versus (Sep'16 Rs 0.85 crore). Operating Profit surged by 45.68 per cent to Rs 21.75 crore as against Rs 14.93 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 37.36 per cent in September quarter. Interest declined by 47.90 per cent y-o-y to Rs 1.61 crore, while Taxation increased by 156.31 per cent at Rs 5.69 crore (Sep'16 Rs 2.22 crore).

24-11-2017 16:50

Skyline Millars posts Q2 net loss of Rs 0.16 cr

The company reported standalone net loss during the quarter stood at Rs 0.16 crore compared to net profit of Rs 0.53 crore in the previous year quarter. Net revenue of the company rose two fold by 245.45 per cent at Rs 1.14 crore in July-September quarter of this fiscal as against Rs 0.33 crore in the corresponding period last year. During July-September quarter, operating expenses increased by 7.37 per cent to Rs 1.02 crore from Rs 0.95 crore in year ago period. Other Income dipped by 99.43 per cent at Rs 0.01 crore versus (Sep'16 Rs 1.74 crore). Operating Profit surged by 119.35 per cent to Rs 0.12 crore as against Rs -0.62 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 105.56 per cent in September quarter.

24-11-2017 16:40

Kingfa Science & Technology Q2 net profit up 21.77%

The company reported standalone net profit of Rs 5.09 crore for the quarter ended September 30, 2017 as compared to Rs 4.18 crore in the same period last year, registering a year-on-year growth of 21.77 per cent. Net revenue of the company rose substantially by 24.78 per cent at Rs 139.87 crore in July-September quarter of this fiscal as against Rs 112.09 crore in the corresponding period last year. During July-September quarter, operating expenses increased by 23.44 per cent to Rs 130.01 crore from Rs 105.32 crore in year ago period. Other Income grew by 1058.33 per cent at Rs 1.15 crore versus (Sep'16 Rs -0.12 crore). Operating Profit surged by 45.86 per cent to Rs 9.86 crore as against Rs 6.76 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 16.92 per cent in September quarter. Interest grew by 257.75 per cent y-o-y to Rs 1.12 crore, while Taxation increased by 68.61 per cent at Rs 3.76 crore (Sep'16 Rs 2.23 crore).

24-11-2017 16:30

Valiant wins orders worth Rs 5 cr for metro projects

Valiant Communications on Friday said it has received the product approvals and letter of intents for supply of its communication solutions for Kolkata Metro Rail Corporation and Dedicated Freight Corridor projects for western Region. “The gross value of the projects exceeds Rs 5 crore,” Valiant Communications said in a filing to the Bombay Stock Exchange. Commenting on the development, Inder Mohan Sood, Managing Director said: “These are significant developments, as it also opens up the railway sector for the company to participate in the upgradation of Indian Railways.” Meanwhile, shares of company closed trade at Rs 84.00 apiece, up 6.94 per cent, on the BSE today.

24-11-2017 16:16

Alexander Stamps Q2 net profit up 6.25% at Rs 0.17 cr

The company reported standalone net profit of Rs 0.17 crore for the quarter ended September 30, 2017 as compared to Rs 0.16 crore in the same period last year, registering a year-on-year growth of 6.25 per cent. Net revenue of the company declined substantially by 57.74 per cent at Rs 1.31 crore in July-September quarter of this fiscal as against Rs 3.10 crore in the corresponding period last year. During July-September quarter, operating expenses dropped by 62.76 per cent to Rs 1.08 crore from Rs 2.90 crore in year ago period. Operating Profit surged by 15.00 per cent to Rs 0.23 crore as against Rs 0.20 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 169.71 per cent in September quarter. Taxation increased by 40.00 per cent at Rs 0.07 crore (Sep'16 Rs 0.05 crore).

24-11-2017 15:10

Aarti Drugs Ltd - Press Release / Media Release

Press Release for the Quarter September, 2017.

14-Nov-2017 11:33 AM

Aarti Drugs Ltd - Press Release

Aarti Drugs Limited has informed the Exchange regarding a press release dated November 14, 2017, titled Press Release for the Quarter September, 2017..

14-Nov-2017 11:28 AM

Aarti Drugs Ltd Q2 net profit down 10.30% at Rs 18.03 cr

The company reported standalone net profit of Rs 18.03 crore for the quarter ended September 30, 2017 as compared to Rs 20.10 crore in the same period last year, registering a year-on-yeardeclineof 10.30 per cent. Net revenue of the company rose by 0.54 per cent at Rs 288.20 crore in July-September quarter of this fiscal as against Rs 286.66 crore in the corresponding period last year. During July-September quarter, operating expenses increased by 1.93 per cent to Rs 244.16 crore from Rs 239.54 crore in year ago period. Other Income grew by 0.00 per cent at Rs 0.08 crore versus (Sep'16 Rs 0.00 crore). Operating Profit slipped by 7.52 per cent to Rs 44.04 crore as against Rs 47.62 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 8.01 per cent in September quarter. Interest declined by 8.65 per cent y-o-y to Rs 7.60 crore, while Taxation decreased by 9.09 per cent at Rs 9.00 crore (Sep'16 Rs 9.90 crore).

13-Nov-2017 02:38 PM

Aarti Drugs Ltd - Financial Results For The Quarter And Half Year Ended 30Th September, 2017.

Outcome of Board Meeting held today i.e. 13th November, 2017 pursuant to Regulation 33 and 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

13-Nov-2017 02:04 PM

Aarti Drugs Ltd - Outcome of Board Meeting

Aarti Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on November 13, 2017 pursuant to Regulation 33 and 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

13-Nov-2017 02:01 PM

Aarti Drugs Ltd - Press Release / Media Release

Press Release for the Quarter September, 2017.

14-Nov-2017 11:33 AM

Aarti Drugs Ltd - Financial Results For The Quarter And Half Year Ended 30Th September, 2017.

Outcome of Board Meeting held today i.e. 13th November, 2017 pursuant to Regulation 33 and 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

13-Nov-2017 02:04 PM

Aarti Drugs Ltd - Updates

Intimation under Regulation 33(3)(b)(i) of SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015.

02-Nov-2017 03:38 PM

Corporate Details

About Management

Aarti Drugs Limited was incorporated on 28th September, 1984 as a Private Limited Company. It was converted into a Public Limited Company on 1st July, 1992. The Company is presently engaged in the manufacture of MNI(300 TPA), MTZ (96 TPA), TNZ (84 TPA), DMZ (90 TPA) and Isoniazid (INH) (96 TPA). The Company started its commercial production is March 1987 at G.I.D.C. Industrial Estate, Sarigam, Dist. Valsad, Gujarat. This project was put up with financial assistance from Gujarat State Finance Corporation (GSFC) and Gujarat Industrial Investment Corporation (GIIC). The Company now proposes to expand the capacities for the above products, except INH and also proposes to set up a new plant for the manufacture of Glyoxal and Ammonium Sulphate. The Company has been consistently making profits and has maintained an unbroken dividend record since the year 1990-91. The Company is a part of the Alchemie Group of Companies. The Company is promoted by Mr. Chandrakant V.Gogri, Mr.Rajendra V.Gogri and Mr. Shantilal T. Shah. Mr. P.M. Patil and Mr. S. P. Nachane joined the Group in 1981. The Alchemie Group is a professionally managed, multi-product, multilocation Group comprising 24 manufacturing units with a total turnover of over Rs.100 crores for the year 1991-92. The products of the Group, exceeding 40, range from industrial chemicals and dye intermediates to bulk drugs and fine chemicals. The Group's customer list includes most of the leading chemical companies in the country. The Group's turnover and profits have increased five-fold in the last 5 years. It also recorded an export turnover of more than Rs. 30 crores in the year 1991-92. The Group units export products mainly to the general currency areas such as USA, UK, Switzerland and Germany. 2000 - The Company proposed to acquire 15,31,000 No. of equity shares of Alchemie Organics Ltd 33.44 per cent of the total paid-up capital of AOL held by the other promoters. 2002-Gauri Balankhe appointed as Compliance Officer of Aarti Drugs. 2004 -Aarti Drugs Ltd. has informed that the Company has changed its Registrar and Share Transfer Agent and Depository interface for Handling Depository related operations by appointing M/s Sharepro Services in place of M/s R & D Consultants Ltd w.e.f. January 16, 2004 subject to completion of necessary formalities as maybe prescribed in this regard. The address and telephone number of M/s Sharepro Services for all investors related services are as under: 1. M/s Sharepro Services, Unit : Aarti Drugs Ltd; 912, Raheja Centre, Free Press Journal Road, Nariman Point, Mumbai 400 021, Tel nos : 22881569, 22884527. 2. M/s Sharepro Services, Unit : Aarti Drugs Ltd; 912, Satam Estate, 3rd Floor, Above Bank of Baroda, Chakla, Andheri (East), Mumbai 400 099, Tel nos : 28215168, 28319828; Fax nos : 28375646. -Aarti bags European certification for three drugs -Delist from Ahmedabad Stock Exchange (ASE) with effect from October 15, 2004. 2006 -Aarti Drugs enters into JV with API Manufacturing Chinese Company - Aarti Drugs Ltd. has informed that Mr. Prakash Khedekar, Company Secretary & Compliance Officer of the Company has resigned from the position of Company Secretary & Compliance Officer with effect from October 31, 2006. Further, Mrs. Mona Patel, possessing requisite qualifications, has been appointed as Company Secretary & Compliance Officer of the Company with effect from November 01, 2006. 2009 - Aarti Drugs Ltd has has appointed Shri Krishnacharya Govindacharya Akamanchi & Prof. Sudhir Prakash B. Sawant as Independent Directors of the Company. 2010 -Aarti Drugs has recommended dividend of Rs. 5/- (50%) per share 2011 -Mr. Sunny D. Pagare, has been appointed as Company Secretary & Compliance Officer of the Company -Aarti Drugs has recommended Final Dividend of Rs. 2.5 /-per share (25%) 2012 -Mr. Adhish P. Patil, has been appointed as Chief Financial Officer of the Company -Aarti Drugs has declared Final dividend Rs. 3.00 (30%) per share 2013 -Aarti Drugs has recommended a Final Dividend of Rs. 4/- per share on Equity Shares of Rs. 10/- each. 2014 -Aarti Drugs has commenced the new R&D center at MIDC Tarapur. -Aarti Drugs has recommended a Final dividend @ Rs. 5.50 ps. (55%) per share. 2015 -Aarti Drugs Ltd has will participate at 'Centrum Pharma Day' Investor Conference -The Company has allotted the Bonus Shares to its shareholders in the Ratio of 1:1.

Registered Office

Plot Nos. D-277/278, TTC Industrial Area, Turbhe

,,,      ,

Registrar Details

Link Intime India Pvt. Ltd.